Assignee
RHIZEN PHARMACEUTICALS SA
CH·43 granted patents·13 pending applications·119 citations·filing 2010–2021
Top patents by PatentIndex Score
56 records- 0197US9150579B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2013·Granted Oct 6, 2015·34 cites·14 claims
- 0296US9475818B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2015·Granted Oct 25, 2016·17 cites·20 claims
- 0394US10072013B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Sep 11, 2018·9 cites·20 claims
- 0494US9669033B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2016·Granted Jun 6, 2017·10 cites·15 claims
- 0593US8921364B2Modulators of calcium release-activated calcium channelRHIZEN PHARMACEUTICALS SA·Filed 2012·Granted Dec 30, 2014·7 cites·23 claims
- 0692US8377970B2Modulators of calcium release-activated calcium channelRHIZEN PHARMACEUTICALS SA·Filed 2010·Granted Feb 19, 2013·7 cites·28 claims
- 0789US9018375B2Substituted chromenes as kinase modulatorsRHIZEN PHARMACEUTICALS SA·Filed 2013·Granted Apr 28, 2015·8 cites·5 claims
- 0888US10414773B2Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulationsRHIZEN PHARMACEUTICALS SA·Filed 2018·Granted Sep 17, 2019·1 cites·28 claims
- 0987US9969740B2Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulationsRHIZEN PHARMACEUTICALS SA·Filed 2015·Granted May 15, 2018·2 cites·29 claims
- 1085US10981919B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2020·Granted Apr 20, 2021·1 cites·13 claims
- 1185US10570142B2Selective PI3K delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2018·Granted Feb 25, 2020·2 cites·29 claims
- 1285US9421209B2Kinase modulatorsRHIZEN PHARMACEUTICALS SA·Filed 2015·Granted Aug 23, 2016·3 cites·13 claims
- 1383US9815831B23,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2013·Granted Nov 14, 2017·5 cites·32 claims
- 1483US9737521B2Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitorRHIZEN PHARMACEUTICALS SA·Filed 2013·Granted Aug 22, 2017·4 cites·21 claims
- 1581US10220035B2Compounds as modulators of protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2015·Granted Mar 5, 2019·2 cites·12 claims
- 1680US9783533B2Glutaminase inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2015·Granted Oct 10, 2017·4 cites·13 claims
- 1780US9758514B2Modulators of calcium release-activated calcium channelRHIZEN PHARMACEUTICALS SA·Filed 2014·Granted Sep 12, 2017·1 cites·47 claims
- 1878US11858907B2Kinase modulatorsRHIZEN PHARMACEUTICALS SA·Filed 2019·Granted Jan 2, 2024·0 cites·18 claims
- 1976US2021403475A1Novel selective pi3k delta inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2021·Application pending·0 cites
- 2074US2021401840A1Novel compounds as modulators of protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2021·Application pending·0 cites
- 2171US9777018B2Compounds as modulators of GPR-119RHIZEN PHARMACEUTICALS SA·Filed 2015·Granted Oct 3, 2017·1 cites·36 claims
- 2270US11466006B2Dual selective PI3 delta and gamma kinase inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2020·Granted Oct 11, 2022·0 cites·10 claims
- 2370US11020399B2Intermediates useful in the synthesis of compounds as modulators of protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2019·Granted Jun 1, 2021·0 cites·2 claims
- 2470US9758474B2Immunomodulator and anti-inflammatory compoundsRHIZEN PHARMACEUTICALS SA·Filed 2014·Granted Sep 12, 2017·1 cites·8 claims
- 2569US10947244B2Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulationsRHIZEN PHARMACEUTICALS SA·Filed 2019·Granted Mar 16, 2021·0 cites·40 claims
- 2669US10668051B2Modulators of calcium release-activated calcium channelRHIZEN PHARMACEUTICALS SA·Filed 2019·Granted Jun 2, 2020·0 cites·20 claims
- 2769US10246450B2Modulators of calcium release-activated calcium channelRHIZEN PHARMACEUTICALS SA·Filed 2018·Granted Apr 2, 2019·0 cites·19 claims
- 2869US2021269446A1Forms of a pi3k delta selective inhibitor for use in pharmaceutical formulationsRHIZEN PHARMACEUTICALS SA·Filed 2020·Application pending·0 cites
- 2968US2021371416A1Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2021·Application pending·0 cites
- 3067US11065236B2Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitorRHIZEN PHARMACEUTICALS SA·Filed 2019·Granted Jul 20, 2021·0 cites·13 claims
- 3167US9944631B2Modulators of calcium release-activated calcium channelRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Apr 17, 2018·0 cites·15 claims
- 3266US2020199133A1Selective dual inhibitors of pi3 delta and gamma protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2020·Application pending·0 cites
- 3364US10413532B2Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitorRHIZEN PHARMACEUTICALS SA·Filed 2018·Granted Sep 17, 2019·0 cites·14 claims
- 3464US2021032236A1Novel glutaminase inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2020·Application pending·0 cites
- 3563US10538501B2Kinase modulatorsRHIZEN PHARMACEUTICALS SA·Filed 2016·Granted Jan 21, 2020·0 cites·22 claims
- 3663US10058539B2Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitorRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Aug 28, 2018·0 cites·33 claims
- 3762US9790224B2Dual selective PI3 delta and gamma kinase inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2014·Granted Oct 17, 2017·0 cites·32 claims
- 3861US10851107B2Dual selective P13 delta and gamma kinase inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Dec 1, 2020·0 cites·23 claims
- 3961US10611759B2Glutaminase inhibitorsRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Apr 7, 2020·0 cites·25 claims
- 4061US10322130B2Substituted chromenones as modulators of protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Jun 18, 2019·0 cites·35 claims
- 4161US10179786B2Selective dual inhibitors of PI3 delta and gamma protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Jan 15, 2019·0 cites·5 claims
- 4261US2019202836A1Selective dual inhibitors of pi3 delta and gamma protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2018·Application pending·0 cites
- 4358US2021030757A1Method of treatment and compositions comprising a dual p13k delta-gamma kinase inhibitor and a corticosteroidRHIZEN PHARMACEUTICALS SA·Filed 2020·Application pending·0 cites
- 4457US9708329B2Selective dual inhibitors of PI3 delta and gamma protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2015·Granted Jul 18, 2017·0 cites·10 claims
- 4556US11478481B2Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticalsRHIZEN PHARMACEUTICALS SA·Filed 2018·Granted Oct 25, 2022·0 cites·5 claims
- 4655US11066402B23,5-disubstituted-3H-imidazo[4,5-b]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinasesRHIZEN PHARMACEUTICALS SA·Filed 2017·Granted Jul 20, 2021·0 cites·19 claims
- 4754US10130635B2Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticalsRHIZEN PHARMACEUTICALS SA·Filed 2016·Granted Nov 20, 2018·0 cites·15 claims
- 4854US2019248791A1Novel modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancerRHIZEN PHARMACEUTICALS SA·Filed 2018·Application pending·0 cites
- 4954US2017342089A1Novel compounds as modulators of gpr-119RHIZEN PHARMACEUTICALS SA·Filed 2017·Application pending·0 cites
- 5052US2020289520A1Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphomaRHIZEN PHARMACEUTICALS SA·Filed 2018·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when RHIZEN PHARMACEUTICALS SA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →